Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,181 to 2,200 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Losartan 50 mg vs Losartan 150 mg: serious adverse events | 691 of 1,913 710 of 1,921 | -0.8 points -3.9 to 2.2 | 3,834 | NCT00090259 Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948) |
| Good School Toolkit vs Control: Physical Violence From School Staff | 595 of 1,921 924 of 1,899 | -17.7 points -20.7 to -14.6 | 3,820 | NCT01678846 Good Schools Study |
| Matched Treated: Absence Eligibility vs Matched Untreated: Absence Eligibility: Number of Participants With Presence of Any Absence Records: Matched Participants | 1,255 of 1,909 1,331 of 1,909 | -4.0 points -6.9 to -1.0 | 3,818 | NCT07072793 A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe |
| Daprodustat vs Darbepoetin Alfa: Number of Participants With at Least One BP Exacerbation Event During Study | 939 of 1,919 1,012 of 1,884 | -4.8 points -7.9 to -1.6 | 3,803 | NCT02876835 Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) |
| Vaccine vs Placebo: Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- PP Cohort | 1 of 2,855 47 of 945 | -4.9 points -6.5 to -3.7 | 3,800 | NCT00382408 A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001 |
| Donning Non-Sterile Gloves Without Hand Hygiene vs Hand Hygiene Before Donning Non-Sterile Gloves: Number of Participants With Composite Compliance With Expected Infection Prevention Practices Upon Entry to Contact Precaution-patient Rooms | 1,297 of 1,491 954 of 2,299 | 45.5 points 42.8 to 48.1 | 3,790 | NCT03119389 Direct Gloving Strategy: A Cluster-randomized Trial |
| Donning Non-Sterile Gloves Without Hand Hygiene vs Hand Hygiene Before Donning Non-Sterile Gloves: Proportion of Healthcare Worker Who Use Glove on Entry Into Contact Precaution Rooms | 1,297 of 1,491 1,530 of 2,299 | 20.4 points 17.8 to 23.0 | 3,790 | NCT03119389 Direct Gloving Strategy: A Cluster-randomized Trial |
| Intervention Group vs Wait List Control Group: Initiation of the HPV Vaccine 2-dose Series. | 1,723 of 2,151 1,219 of 1,615 | 4.6 points 1.9 to 7.3 | 3,766 | NCT04180462 Increasing Optimal Use of HPV Vaccination in Primary Care |
| Intervention Group vs Wait List Control Group: Completion of the HPV Vaccine 2-dose Series. | 1,135 of 2,151 809 of 1,615 | 2.7 points -0.6 to 5.9 | 3,766 | NCT04180462 Increasing Optimal Use of HPV Vaccination in Primary Care |
| Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: Guideline-concordant Decision to Not Prescribe Antibiotics for Adult Pharyngitis | 1,432 of 1,432 2,312 of 2,317 | 0.2 points -0.1 to 0.5 | 3,749 | NCT06027593 Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions |
| Cervarix Group vs Placebo Group: Number of Subjects With Unsolicited Adverse Events for Subjects Seronegative and DNA Negative for Both HPV-16 and HPV-18 at Baseline | 497 of 1,892 468 of 1,843 | 0.9 points -1.9 to 3.7 | 3,735 | NCT00779766 Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects |
| Cervarix Group vs Placebo Group: Number of Subjects With Medically Significant Conditions Regardless of Causal Relationship to Vaccination and Intensity for Subjects Seronegative and DNA Negative for Both HPV-16 and HPV-18 at Baseline | 122 of 1,892 110 of 1,843 | 0.5 points -1.1 to 2.0 | 3,735 | NCT00779766 Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects |
| 10 mg Empagliflozin vs Placebo: deaths from any cause | 249 of 1,863 266 of 1,867 | -0.9 points -3.1 to 1.3 | 3,730 | NCT03057977 EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) |
| 10 mg Empagliflozin vs Placebo: serious adverse events | 772 of 1,863 896 of 1,863 | -6.7 points -9.8 to -3.5 | 3,726 | NCT03057977 EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) |
| Three-chambered Bag (3CB) vs Hospital-Compounded Bag (HCB): Treatment With Antimicrobials During PN | 831 of 2,753 370 of 970 | -8.0 points -11.5 to -4.5 | 3,723 | NCT03284398 Three-Chamber Bags Retrospective Study in Spain |
| Three-Chambered Bag (3CB) vs Hospital-compounded Bag (HCB): Renal Replacement Therapy | 78 of 2,753 89 of 970 | -6.3 points -8.4 to -4.5 | 3,723 | NCT03284398 Three-Chamber Bags Retrospective Study in Spain |
| Three-Chambered Bag (3CB) vs Hospital-compounded Bag (HCB): Use of Mechanical Ventilation | 410 of 2,753 299 of 970 | -15.9 points -19.2 to -12.8 | 3,723 | NCT03284398 Three-Chamber Bags Retrospective Study in Spain |
| Three-Chambered Bag (3CB) vs Hospital-Compounded Bag (HCB): Sepsis During PN | 431 of 2,753 228 of 970 | -7.8 points -10.9 to -4.9 | 3,723 | NCT03284398 Three-Chamber Bags Retrospective Study in Spain |
| Three-Chambered Bag vs Hospital-compounded Bag: Percentage of Patients Presenting With a Confirmed Microbial Blood Stream Infection During Treatment With PN for Each Group (3CB vs HCB) | 127 of 2,753 106 of 970 | -6.3 points -8.6 to -4.3 | 3,723 | NCT03284398 Three-Chamber Bags Retrospective Study in Spain |
| Three-Chambered Bag (3CB) vs Hospital-compounded Bag (HCB): Use of Vasopressor Treatment | 410 of 2,753 291 of 970 | -15.1 points -18.3 to -12.0 | 3,723 | NCT03284398 Three-Chamber Bags Retrospective Study in Spain |
Code
curl "https://conductscience.org/api/comparisons/v1?page=110"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=110
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00090259-sae",
"title": "Losartan 50 mg vs Losartan 150 mg: serious adverse events",
"summary": "691 of 1913 against 710 of 1921; risk difference -0.8 points, 95% interval -3.9 to 2.2; NCT00090259, Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)",
"record": "/library/comparisons/NCT00090259-sae",
"nct_id": "NCT00090259",
"kind": "serious-adverse-events",
"participants": 3834,
"risk_difference": {
"value": -0.008386412265131371,
"lower": -0.03883242426312185,
"upper": 0.022083845915999968
},
"group_1": "691 of 1,913",
"group_2": "710 of 1,921",
"difference": "-0.8 points",
"interval": "-3.9 to 2.2",
"trial_title": "Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)"
},
{
"id": "NCT01678846-392ea22b",
"title": "Good School Toolkit vs Control: Physical Violence From School Staff",
"summary": "595 of 1921 against 924 of 1899; risk difference -17.7 points, 95% interval -20.7 to -14.6; NCT01678846, Good Schools Study",
"record": "/library/comparisons/NCT01678846-392ea22b",
"nct_id": "NCT01678846",
"kind": "outcome",
"participants": 3820,
"risk_difference": {
"value": -0.17683736666247257,
"lower": -0.20711670810520494,
"upper": -0.14608378154577525
},
"group_1": "595 of 1,921",
"group_2": "924 of 1,899",
"difference": "-17.7 points",
"interval": "-20.7 to -14.6",
"trial_title": "Good Schools Study"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=111",
"request_id": "bt5Yz4PB6CpXG0ie"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant